Progression in attenuating myocardial reperfusion injury: An overview

Bernink, Flip J.P.; Timmers, Leo; Beek, Aernout M.; Diamant, Michaëla; Roos, Sebastiaan T.; Rossum, Albert C. van; Appelman, Yolande

doi:10.1016/j.ijcard.2013.11.007

Cited by 44 publications

(22 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myocardial ischemia/reperfusion injury in mice was induced by ligation of the left descending coronary artery, involving calcium overload, oxygen free radical injury, inflammation and other damage, and simulated myocardial infarction induced by clinical coronary heart disease. After reperfusion, the oxygen in the blood could react with the dissolved substances of damaged myocardium cells to form the secondary injury in myocardium [35]. The model of chronic intermittent hypoxia in mice could simulate the heart palpitations and cardiac hypertrophy, eventually lead to the cardiac dysfunction and heart failure, meanwhile, could also simulate the apparent indications of deficiency of both Qi and Yin syndrome [22].…”

Section: Discussionmentioning

confidence: 99%

A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia

Li¹,

Fan²,

Cai³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Traditional Chinese medicine (TCM) has been used in clinical practice for thousands of years and has accumulated considerable knowledge concerning the in vivo efficacy of targeting complicated diseases. TCM formulae are a mixture of hundreds of chemical components with multiple potential targets, essentially acting as a combination therapy of multi-component drugs. However, the obscure substances and the unclear molecular mechanisms are obstacles to their further development and internationalization. Therefore, it is necessary to develop new modern drugs based on the combination of effective components in TCM with exact clinical efficacy. In present study, we aimed to detect optimal ratio of the combination of effective components based on Sheng-Mai-San for myocardial ischemia. Methods: On the basis of preliminary studies and references of relevant literature about Sheng-Mai-San for myocardial ischemia, we chose three representative components (ginsenoside Rb1 (G), ruscogenin (R) and schisandrin (S)) for the optimization design studies. First, the proper proportion of the combination was explored in different myocardial ischemia mice induced by isoproterenol and pituitrin based on orthogonal design. Then, the different proportion combinations were further optimized through uniform design in a multi-model and multi-index mode. Finally, the protective effect of combination was verified in three models of myocardial ischemia injured by ischemia/reperfusion, chronic intermittent hypoxia and acute infarction. Results: The optimized combination GRS (G: 6 mg/kg, R: 0.75 mg/kg, S: 6 mg/kg) obtained by experimental screening exhibited a significant protective effect on myocardial ischemia injury, as evidenced by decreased myocardium infarct size, ameliorated histological features, decreased myocardial myeloperoxidase (MPO) and malondiadehyde (MDA), calcium overload, and decreased serum lactate dehydrogenase (LDH), creatine kinase MB isoenzyme (CK-MB), cardiac troponin I (cTn-I) activity. In addition, the interactions of three components in combination GRS were also investigated. The combination, compared to G, R and S, could significantly reduce the concentration of serum CK-MB and cTn-I, and decrease myocardial infarct size, which demonstrated the advantages of this combination for myocardial ischemia. Conclusion: Our results demonstrated that the optimized combination GRS could exert significant cardioprotection against myocardial ischemia injury with similar effect compared to Sheng Mai preparations, which might provide some pharmacological evidences for further development of new modern Chinese drug for cardiovascular diseases basing on traditional Chinese formula with affirmative therapeutic effect.

show abstract

Section: Discussionmentioning

confidence: 99%

A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia

Li¹,

Fan²,

Cai³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Recently, exenatide therapy was shown to increase myocardial salvage [12] and decrease final infarct size [13] in ST elevated myocardial infarction patients successfully treated with percutaneous coronary intervention. Exenatide is therefore considered one of the most promising compounds to reduce infarct size [14]. The current study was designed to investigate the effect of exenatide on myocardial infarct size as a percentage of the area at risk (AAR) in patients with ST elevated myocardial infarction who underwent successful percutaneous coronary intervention.…”

Section: Introductionmentioning

confidence: 99%

No benefit of additional treatment with exenatide in patients with an acute myocardial infarction

Roos

Timmers

Biesbroek

et al. 2016

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…MVO, largely caused by obstruction of the microcirculation with atherothrombotic debris, results in local inflammation, platelet aggregation, myocardial edema due to dysfunctional endothelium, and formation of in situ microvascular thrombi (Ito 2014; Robbers et al 2013). While many preventative and curative strategies have been employed (Bernink et al 2014; Fröhlich et al 2013; Galasso et al 2014), there has been no consistently efficacious therapeutic approach.…”

Section: Introductionmentioning

confidence: 99%

Sonoreperfusion Therapy Kinetics in Whole Blood Using Ultrasound, Microbubbles and Tissue Plasminogen Activator

Roos

Kamp

et al. 2016

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Coronary intervention for myocardial infarction often results in microvascular embolization of thrombus. Sonoreperfusion therapy (SRP) using ultrasound and microbubbles restored perfusion in our in vitro flow model of microvascular obstruction. In this study, we assessed SRP efficacy using whole blood as the perfusate with and without tissue plasminogen activator (tPA). In a phantom vessel bearing a 40-μm pore mesh to simulate the microvasculature, microthrombi were injected to cause microvascular obstruction and were treated using SRP. Without tPA, the lytic rate increased from 2.6±1.5 mmHg/min with 1000 cycles to 7.3±3.2 mmHg/min with 5000 cycles ultrasound pulses (p<0.01). The lytic index was similar between tPA-only [(2.0±0.5)×10−3 mmHg−1min−1] and 5000 cycles without tPA [(2.3±0.5)×10−3 mmHg−1min−1] (p=0.5) but increased [(3.6±0.8)×10−3 mmHg−1min−1] with tPA in conjunction with 5000 cycles ultrasound (p<0.01). In conclusion, SRP restored microvascular perfusion in whole blood and SRP lytic rate in experiments without tPA increased with ultrasound pulse length and efficacy increased with the addition of tPA.

show abstract

Progression in attenuating myocardial reperfusion injury: An overview

Cited by 44 publications

References 92 publications

A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia

A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia

No benefit of additional treatment with exenatide in patients with an acute myocardial infarction

Sonoreperfusion Therapy Kinetics in Whole Blood Using Ultrasound, Microbubbles and Tissue Plasminogen Activator

Contact Info

Product

Resources

About